Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03614494
Other study ID # UW18-003
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date August 20, 2018
Est. completion date October 5, 2022

Study information

Verified date November 2023
Source The University of Hong Kong
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomised controlled trial aimed at comparing the efficacy of levonorgestrel (LNG) co-administered with piroxicam or placebo for oral emergency contraception (EC). Piroxicam is a non-steroidal anti-inflammatory drug (NSAID) commonly used as a pain-killer in inflammatory conditions. Efficacy will be measured as the percentage of pregnancies prevented.


Description:

Objective: To compare the percentage of pregnancies prevented by LNG co-administered with piroxicam or placebo for oral emergency contraception (EC) by a randomised controlled trial. Hypothesis to be tested: LNG plus piroxicam has higher percentage of pregnancies prevented compared with LNG plus placebo for oral emergency contraception. Design and subjects: This will be a prospective, randomised placebo-controlled clinical trial. Women attending the Family Planning Association of Hong Kong for oral EC within 72 hours of unprotected sexual intercourse will be recruited. Study instruments: Prospective follow-up of subjects in the clinic for the primary and secondary outcomes. Interventions: Eligible subjects will be randomised to receive one of the two treatment regimens, i.e. Group A: a single dose of LNG 1.5 mg and piroxicam 40 mg, or Group B: a single dose of LNG 1.5mg and placebo under direct supervision. Main outcome measures: Percentage of pregnancies prevented (PPP) is the primary outcome measure. Secondary outcome measures include failure rate, rate of occurrence of side effects and pattern of the menstruation following EC. Data analysis:The percentage of pregnancies prevented, failure rate and rate of occurrence of side effects will be compared between groups using Fisher-Exact test. Continuous variables regarding menstrual pattern between the two groups will be compared by Mann-Whitney U test. Expected results: LNG plus piroxicam has a higher PPP compared to LNG plus placebo.


Recruitment information / eligibility

Status Completed
Enrollment 860
Est. completion date October 5, 2022
Est. primary completion date October 5, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - healthy women aged 18 years or above; - requesting emergency contraception within 72 h of a single act of unprotected intercourse in the current menstrual cycle; - having menstrual cycles between 24 and 42 days - willing to abstain from further acts of unprotected intercourse and; - available for follow-up over the next 6 weeks. Exclusion Criteria: - post-abortion or postpartum and period have not yet returned, - being on prescription drugs currently - having unprotected intercourse in this cycle more than 72 hours or more than once before attending the clinic, - being found pregnant at the time of presentation, - breastfeeding, - having been sterilized (or partner having been sterilized) or having intrauterine contraceptive device in-situ, - uncertain about the date of the last menstrual period, - having used hormonal contraceptive (including EC pill) or NSAID in the current or past one cycle, - having history of asthma, urticarial or other allergic reactions to piroxicam, aspirin or other NSAIDs, - having history of ischaemic heart disease in the past one year - having history of pelvic ulcer disease and/or gastrointestinal bleeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Piroxicam 40 mg
Additional co-treatment
Levonorgestrel 1.5mg
Standard treatment

Locations

Country Name City State
Hong Kong Queen Mary Hospital Hong Kong
Hong Kong The Family Planning Association of Hong Kong Hong Kong

Sponsors (2)

Lead Sponsor Collaborator
Dr. Hang Wun Raymond Li The Family Planning Association of Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Pregnancies Prevented (number of expected pregnancies - number of observed pregnancies) / number of expected pregnancies. The number of expected pregnancies is calculated based on the cycle day on which unprotected sexual intercourse occurred in each woman according to the model published by Trussel et al (Trussell J et al, Contraception 2003; 67:259-265). 1 month
Secondary Pregnancy Rate number of participants who were pregnant / number of efficacy-evaluable participants 1 month
See also
  Status Clinical Trial Phase
Completed NCT00271583 - Efficacy Trial of CDB 2914 for Emergency Contraception Phase 2/Phase 3
Completed NCT00777556 - Emergency Contraception Actual Use Study Phase 3
Completed NCT00677755 - Medical Abortion for Emergency Contraception Failure N/A
Recruiting NCT06162611 - Etonogestrel (ENG) Implant Insertion for Emergency Contraception With Oral Levonorgestrel (LNG) vs Placebo Phase 4
Completed NCT00411684 - Safety and Efficacy of CDB-2914 for Emergency Contraception Phase 3
Completed NCT01569737 - Clinical Follow-up and Outcomes of Pregnancies Exposed to Ella
Completed NCT03208985 - A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions Phase 3
Completed NCT02078414 - Continued Use of Effective Contraception After Use of Emergency Contraception
Completed NCT01569113 - Assessment of Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® or Placebo. Phase 4
Completed NCT01963962 - Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception N/A
Recruiting NCT03120728 - Application for the Etonogestrel/Ethinyl Estradiol Ring Phase 4
Active, not recruiting NCT02076217 - Quick Start of Highly Effective Contraception
Not yet recruiting NCT04172584 - Awareness & Use of Emergency Contraception
Completed NCT03395756 - Depot Medroxyprogesterone Acetate as Emergency Contraception Early Phase 1